Never heard of Common Sense Oncology?? Well if you enjoy this podcast then we think you will might find the Common Sense Oncology (CSO) movement to be very interesting indeed!

Declan Murphy caught up recently with Dr Bishal Gyawali, Medical Oncologist at Queen's University, Kingston, Ontario, to talk about CSO which he co-founded in 2023. They are on a mission to ensure that cancer care and innovation, should focus on results that are meaningful to patients (eg survival, quality of life, equity), rather than just regulatory approval, commercial success, or statistical endpoints. "Outcomes that matter", is their battle cry.

They are also very focussed on communication, and are quick to call out when stakeholders make ridiculous claims for their product or innovation. And Bishal happens to be one of the very best communicators out there. Great to have him on GU Cast and we at GU Cast are 100% supportive of their mission.

You can visit their website and join the movement for all the latest updates

The Urological Association of Asia (UAA) Annual Meeting is always a great cultural event with a focus on the local community. And Taipei certainly put on a great show! Lots of fantastic entertainment and great local cuisine, plus of course a great scientific program, with a focus on AI, single port robotic surgery, novel robot systems, and lots more across the breadth of Urology.

Join hosts Renu Eapen and Declan Murphy, who bring you a great flavour of UAA in Taipei, speaking to many local and international guests. 

Even better on our YouTube channel

GU Cast Conference Highlights are supported by our Conference Highlights Partner, Bayer China. 

They started off by introducing themselves as The Three Horsemen of the Apocalypse - what could possibly go wrong!! Declan couldn't resist the opportunity to invite three very eminent radiation oncologists into the studio when they all happened to be in Melbourne, even if he was particularly outnumbered while Renu was away! Vedang Murthy (Tata Memorial, India), Andrew Loblaw (Sunnybrook Hospital, Canada), and Sarat Chander (Peter Mac, Melbourne) are all highly specialised in prostate radiation, so Declan invited them into the GU Cast studio to pick their brains on three big areas in prostate radiation:
1. Hypofractionation in 2025 - Who and How?
2. Who needs ADT and for how long when having prostate radiation?
3. Metastasis-directed therapy for oligometastatic disease - is there any point??

Tune in to find out how Urologist Declan Murphy fared up against these three Radiation Oncologists!!! Even better on our YouTube channel

This podcast is supported by our Bronze Partner, Icon Cancer Centre.

We never need an excuse to visit Sydney, and for sure when one of our favourite meetings of the year is in the Harbourside City then count us in! The Annual Meeting of ANZUP is something we try and get to every year and have really enjoyed bringing you highlights. This year we catch up with some international faculty including Roger Li (Moffitt Cancer Centre, USA), ANZUP Prostate Cancer Committee bosses Lisa Horvath (Chris O'Brien Lifehouse) and Jarad Martin (Genesis Care), Dickon Hayne (Fiona Stanley Hospital) regarding his NMICB RCT, and Bernie Reilly (Prostate CAncer Foundation of Australia) about some fantastic resources for prostate cancer patients. 

Big congrats to all at ANZUP for another excellent meeting and for all they do for GU oncology in Australia and New Zealand. 

PS - apologies for some sub-standard audio on this one. 

GU Cast Conference Highlights are supported by our Conference Highlights Partner, Bayer.

Episode 2 of our monthly GU Cast Journal Club and today we focus on two key papers from recent times - the TRANSLATE trial of transperineal vs transrectal biopsy, and Keynote-564 on the role of adjuvant pembrolizomab following nephrectomy.   
After great feedback from last month's launch episode, we are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and  Declan Murphy

Links to papers and previous podcasts below:
1. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial Lancet Oncology 2025
GU Cast on TRANSLATE

2. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma NEJM 2024
GU Cast on K-564 OS paper

GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.

Even better on our YouTube channel

About GU Cast Journal Club:
Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology
. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner
. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

We poke around under the hood of a brand new Cyberknife facility here in Melbourne, the first on the East coast of Australia, and find out what it's all about. What is it for, who might benefit, and being surgeons we have to ask, why do they call it a "knife"?! Is it just to make it sound a bit like surgery - stay tuned to find out! 
We chat with our good mate Shankar Siva, stereotactic radiation guru, Nigel Middlebrook, Physicist, shows us the back end, Gemma Waters, Radiation Therapist talks us through planning, and Icon Cancer Group Chief Executive Mark Middleton tells us how he decides which expensive projects his team invests in, and how they partnered with Cyberknife experts 5D Clinics for this project.

Even better on our YouTube channel. 

 
This Themed Episode is supported by our Bronze Partner, Icon Cancer Group.

Links:
5D Clinics Melbourne
Icon Cancer Group 

Big news today with the publication in JAMA of the eagerly anticipated PRIME study, a prospective multicentre trial comparing biparametric (bp) with multiparametric (mp) MRI in men suspected of having prostate cancer. Of course, mpMRI includes contrast enhanced sequences following injection of gadolinium, adding time, cost, plus the burden of gadolinium to bpMRI, and there have been suggestions that bpMRI may be just as effective as mpMRI for detecting clinically significant prostate cancer.
We are joined today by trial PI Veeru Kasivisvanathan (Urologist, UCL, London), and Francesco Giganti (Radiologist, UCL, London), to discuss the findings and what this means going forward. And it is all good news!

Your host Declan Murphy is on his own today while Renu Eapen on the road in Singapore.

Even better on our YouTube channel

Links below:
JAMA paper published today
Twitter:  @compassurology @veerukasi @giga_fra
Website: compassurology.org

Funders:
John Black Charitable Foundation, Prostate Cancer UK, European Association of Urology Research Foundation, Wolfgang.Dieckmann Foundation.

A quick pod to promote the totally free WRSE12 Live Robotic Surgery Event coming up later this month! A 12 hour festival of incredible robotic surgery performed by top surgeons from around the world, with a special focus on real time digital pathology using the very promising Histolog technology that we recently featured on GU Cast. Live surgeries include upper and lower tract, with an array of robotic technology including the da Vinci Single Port robot.
We chat with Urologist Ruben de Groote about this excellent educational initiative from Surgquest, the digital extension of the ORSI Academy in Belgium, and discuss some of the highlights.
See links below for full details and free registration. Plus watch out for a couple of episodes of GU Cast coming up in October/November to bring you highlights and behind the scenes action.

Links:
WRSE12 event free registration

GU Cast on Histology intraoperative margin assessment 

One of our most popular podcasts ever was the one called "Gleason 6 prostate cancer | Why we should rename it (and why we can't)!", posted in December 2022, and featuring Urologists Scott Eggener (Chicago) and Matt Cooperberg), plus Pathologist Eva Comperat (Paris/Vienna). In fact, we still get so many hits on this and active comments on our YouTube site that we thought we better re-visit it!!! Is Gleason 6/Grade Group 1 really cancer at all?? Can't we just re-name it and declare it not-a-cancer??!

Scott and Matt re-join GU Cast today to update us on the campaign!

With usual hosts Renu Eapen and Declan Murphy

Even better on our YouTube channel

Links:
JNCI paper October 2024

Our Dec 2022 podcast on renaming Gleason 6 

Here it is, the first of our new series called GU Cast Journal Club! A dedicated GU Cast Journal Club has been suggested by many of our listeners and viewers over the years, and we are really pleased to kick off today with the first monthly episode. And we are particularly pleased to introduce our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER). Declan Murphy is anchoring today's episode while Renu is busy elsewhere. 
Each month, two papers will be discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology
The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner
The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

 
For this inaugural epsiode, we have selected two very important recent papers:
1. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial

 
2. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer


GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.